Monitoring blood levels of microRNAs in patients with grade 4 gliomas
Monitoring of Patients With Diffuse Gliomas Using Circulating miRNAs
This study is trying to see if tracking certain microRNAs in the blood can help tell the difference between tumor recurrence and tissue damage in patients with grade 4 gliomas after surgery.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Caen Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Caen) |
| Trial ID | NCT06203496 on ClinicalTrials.gov |
What this trial studies
This observational study aims to track the changes in plasma levels of pro-oncogenic microRNAs in patients who have undergone surgery for grade 4 diffuse gliomas. By analyzing blood samples over time, the study seeks to determine if these microRNAs can serve as reliable biomarkers to differentiate between tumor recurrence and radionecrosis. The research is motivated by previous findings that suggest a correlation between serum microRNA levels and tumor progression in gliomas. The study will involve patients treated at Caen University Hospital, ensuring a homogeneous sample for analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are adult patients diagnosed with grade 4 diffuse glioma who have undergone surgical treatment at Caen University Hospital.
Not a fit: Patients with lower-grade gliomas or those who have undergone biopsy instead of surgical excision may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for monitoring glioma recurrence, potentially improving patient management and outcomes.
How similar studies have performed: While preliminary studies have shown promise in using microRNAs as biomarkers for gliomas, this approach is still being validated and is not yet widely established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Major patient * Grade 4 diffuse glioma * Surgery in the neurosurgery department of Caen University Hospital * Patient affiliated to a social security scheme * Patient followed at Caen University Hospital * No opposition from patient Exclusion Criteria: * \- Patients who underwent biopsy (lack of material for study, limited interest of monitoring for these patients without surgical excision). * Patients with grade 1 circumscribed glioma or grade 2 or 3 diffuse glioma. * Other non-glial histologies, glioneuronal histology * Minor patients * Patient not affiliated to a social security scheme * A minor under guardianship or protection * Patient opposed to study
Where this trial is running
Caen
- Arthur Leclerc — Caen, France (Recruiting)
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.